Literature DB >> 18682504

Pentanucleotide repeat polymorphism, lipoprotein(a) levels, and risk of ischemic heart disease.

Pia R Kamstrup1, Anne Tybjaerg-Hansen, Rolf Steffensen, Børge G Nordestgaard.   

Abstract

CONTEXT: Lipoprotein(a) is a cardiovascular risk factor. Levels of lipoprotein(a) are predominantly determined by apolipoprotein(a) gene variation, including a pentanucleotide repeat promoter polymorphism.
OBJECTIVE: We tested the hypothesis that apolipoprotein(a) pentanucleotide repeat genotype predicts elevated lipoprotein(a) levels and risk of myocardial infarction (MI) and ischemic heart disease (IHD) in the general population.
DESIGN: We used a cohort study of the Danish general population, The Copenhagen City Heart Study, including 10,276 individuals of which 860 and 1,781 developed MI and IHD, respectively, during up to 31 yr of follow-up, and a case-control study including 1,814 IHD patients and 5,076 controls. Follow-up was 100% complete.
RESULTS: Allele frequencies were 0.0018, 0.0018, 0.6750, 0.1596, 0.1465, 0.0146, and 0.0004 for 6, 7, 8, 9, 10, 11, and 12 repeats, respectively. Mean lipoprotein(a) levels were 40, 36, and 27 mg/dl for individuals with 14-15, 16, and 17-22 repeats (sum of repeats on both alleles), respectively (trend, P < 0.001). Cumulative incidence of MI and IHD was increased for individuals with 14-15 vs. at least 16 repeats (log rank, P < 0.001 and P = 0.002). Multifactorially adjusted hazard ratios for 14-15 and 17-22 vs. 16 repeats were 3.1 (95% confidence interval, 1.6-5.8) and 1.0 (0.9-1.2) for MI and 2.2 (1.3-3.6) and 1.0 (0.9-1.1) for IHD. In the case-control study, multifactorially adjusted odds ratios for 14-15 and 17-22 vs. 16 repeats were 2.9 (1.1-7.8) and 0.9 (0.8-1.0) for MI and 2.5 (1.0-6.0) and 0.9 (0.8-1.0) for IHD.
CONCLUSIONS: Apolipoprotein(a) 14-15 pentanucleotide repeats predict elevated levels of lipoprotein(a) and a 3- and 2-fold increased risk of MI and IHD in the general population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18682504     DOI: 10.1210/jc.2008-0830

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Clinical assessment incorporating a personal genome.

Authors:  Euan A Ashley; Atul J Butte; Matthew T Wheeler; Rong Chen; Teri E Klein; Frederick E Dewey; Joel T Dudley; Kelly E Ormond; Aleksandra Pavlovic; Alexander A Morgan; Dmitry Pushkarev; Norma F Neff; Louanne Hudgins; Li Gong; Laura M Hodges; Dorit S Berlin; Caroline F Thorn; Katrin Sangkuhl; Joan M Hebert; Mark Woon; Hersh Sagreiya; Ryan Whaley; Joshua W Knowles; Michael F Chou; Joseph V Thakuria; Abraham M Rosenbaum; Alexander Wait Zaranek; George M Church; Henry T Greely; Stephen R Quake; Russ B Altman
Journal:  Lancet       Date:  2010-05-01       Impact factor: 79.321

Review 2.  Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: a systematic in-depth review.

Authors:  Eva Boes; Stefan Coassin; Barbara Kollerits; Iris M Heid; Florian Kronenberg
Journal:  Exp Gerontol       Date:  2008-11-17       Impact factor: 4.032

Review 3.  Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction.

Authors:  Enas A Enas; Basil Varkey; T S Dharmarajan; Guillaume Pare; Vinay K Bahl
Journal:  Indian Heart J       Date:  2019-03-20

4.  A systematic evaluation of short tandem repeats in lipid candidate genes: riding on the SNP-wave.

Authors:  Claudia Lamina; Margot Haun; Stefan Coassin; Anita Kloss-Brandstätter; Christian Gieger; Annette Peters; Harald Grallert; Konstantin Strauch; Thomas Meitinger; Lyudmyla Kedenko; Bernhard Paulweber; Florian Kronenberg
Journal:  PLoS One       Date:  2014-07-22       Impact factor: 3.240

Review 5.  Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies.

Authors:  Ahmed Handhle; Adie Viljoen; Anthony S Wierzbicki
Journal:  Vasc Health Risk Manag       Date:  2021-09-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.